Immunitybio Inc (IBRX)

05:48 AM

How does ImmunityBio Inc. compare to its industry peersDiscover breakthrough investment opportunities - jammulinksnews.com

05:48 AM

05:16 AM

What is ImmunityBio Inc. company’s growth strategyMaximize your portfolio’s growth with expert tips - jammulinksnews.com

05:16 AM

04:54 AM

What institutional investors are buying ImmunityBio Inc. stockAchieve breakthrough performance in the market - jammulinksnews.com

04:54 AM

03:39 AM

Is ImmunityBio Inc. a growth stock or a value stockCapitalize on emerging market opportunities - jammulinksnews.com

03:39 AM

12:43 PM

When is ImmunityBio Inc. stock expected to show significant growthInvest confidently with professional market insights - jammulinksnews.com

12:43 PM

Jul 26, 2025

How ImmunityBio Inc. stock reacts to Fed policy changesMomentum Swing Watchlist - Metal.it

Jul 26, 2025

Jul 25, 2025

ImmunityBio’s Stock Soars: Buy or Sell? - timothysykes.com

Jul 25, 2025

Jul 25, 2025

ImmunityBio (IBRX) Secures $80M Through Direct Offering | IBRX S - GuruFocus

Jul 25, 2025

Jul 25, 2025

Everest Medicines raises $200M; Epirium Bio targets $55M Series B - Endpoints News

Jul 25, 2025

Jul 25, 2025

ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates - BioSpace

Jul 25, 2025

Jul 25, 2025

ImmunityBio announces $80M registered direct offering - TipRanks

Jul 25, 2025

Jul 25, 2025

What analysts say about ImmunityBio Inc. stockHigh-yield investments - PrintWeekIndia

Jul 25, 2025

Jul 25, 2025

ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors - Lelezard

Jul 25, 2025

Jul 25, 2025

ImmunityBio Announces $80 Million Securities Purchase - TipRanks

Jul 25, 2025

Jul 25, 2025

ImmunityBio's Q2 Preliminary Revenue: A Strategic Inflection Point in the Biotech Immune Therapeutics Sector - AInvest

Jul 25, 2025

Jul 25, 2025

ImmunityBio (IBRX) Achieves Significant Revenue Growth in Q2 2025 | IBRX Stock News - GuruFocus

Jul 25, 2025

Jul 25, 2025

ImmunityBio's Q2 Earnings and Revenue Growth: Assessing the Path to Sustainable Value Creation - AInvest

Jul 25, 2025

Jul 24, 2025

Is ImmunityBio Inc. a good long term investmentMarket-leading profit generation - Autocar Professional

Jul 24, 2025

Jul 24, 2025

ImmunityBio’s (IBRX) ANKTIVA Gets Approved by UK’s Medicines and Healthcare Regulatory Agency - MSN

Jul 24, 2025

Jul 22, 2025

What drives ImmunityBio Inc. stock priceConsistently high yield - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

LA Times Going Public? Patrick Soon-Shiong Plans Green Bay-Style Ownership To 'Democratize' 143-Year-Old Paper - Benzinga

Jul 22, 2025

Jul 21, 2025

ImmunityBio: A High-Conviction Play on ANKTIVA's Expanding Indication and Immune-Boosting Platform - AInvest

Jul 21, 2025

Jul 21, 2025

ImmunityBio: Still Flashing Signs Of Life After Another Anktiva Approval - Seeking Alpha

Jul 21, 2025

Jul 20, 2025

ImmunityBio Inc. Stock Analysis and ForecastSkyrocketing returns - jammulinksnews.com

Jul 20, 2025

Jul 15, 2025

ImmunityBio’s Anktiva Rollercoaster: From FDA Rejection and 55% Stock Drop to Approval - TradingView

Jul 15, 2025

Jul 14, 2025

ImmunityBio Settled With Investors Over FDA Rejection Drama— How to Claim Your Share - TradingView

Jul 14, 2025

Jul 12, 2025

ImmunityBio: High Stakes On ANKTIVA's Growth Amidst FDA Friction And Financial Pressures - Seeking Alpha

Jul 12, 2025

Jul 11, 2025

ImmunityBio’s Innovative Approach to Ovarian Cancer: A Phase 2 Study Update - TipRanks

Jul 11, 2025

Jul 10, 2025

Bullish Sentiments for ImmunityBio (IBRX) After Trial Success and FDA Authorization - MSN

Jul 10, 2025

Jul 09, 2025

ImmunityBio Stock Surges Amid Promising Trial Updates - TipRanks

Jul 09, 2025

Jul 09, 2025

ImmunityBio’s Innovative Approach to Bladder Cancer Treatment: A Clinical Study Update - TipRanks

Jul 09, 2025

Jul 08, 2025

ImmunityBio Granted UK Approval for Bladder Cancer Treatment - MarketScreener

Jul 08, 2025

Jul 08, 2025

ImmunityBio: D. Boral Capital Maintains Buy, Raises PT to $30 from $30 - AInvest

Jul 08, 2025

Jul 08, 2025

Why ImmunityBio, Inc. (IBRX) Surged On Thursday - MSN

Jul 08, 2025

Jul 07, 2025

UK MHRA Approves ImmunityBio's ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ - Lelezard

Jul 07, 2025

Jul 07, 2025

ImmunityBio's ANKTIVA® Secures UK Approval: A Catalyst for Global Oncology Leadership - AInvest

Jul 07, 2025

Jul 07, 2025

Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ - Business Wire

Jul 07, 2025

Jul 07, 2025

ImmunityBio ($IBRX) Is Paying a $10.5M Settlement to Investors — Here’s How to Get Your Share - TradingView

Jul 07, 2025

Jul 06, 2025

13 Stocks Under $5 With High Upside Potential - Insider Monkey

Jul 06, 2025

Jul 04, 2025

UK Approves Intravesical Therapy Targeting Bladder Cancer - Vax-Before-Travel

Jul 04, 2025

Jul 02, 2025

ImmunityBio (IBRX) Rated Buy After FDA Approvals and Pancreatic Cancer Trial Success - Yahoo Finance

Jul 02, 2025

Jun 24, 2025

ImmunityBio (IBRX) Attains FDA’s Expanded Access Authorization for its Cancer BioShield Platform Anchored by ANKTIVA - Yahoo Finance

Jun 24, 2025

Jun 23, 2025

Anktiva Approved For Additional Treatment - Los Angeles Business Journal

Jun 23, 2025